Temozolomide in malignant gliomas: current use and future targets J. Lee VillanoTara E. SeeryLinda R. Bressler Mini Review 19 June 2009 Pages: 647 - 655
Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study Jeeyun LeeKyung Hae JungWon Ki Kang Original Article 24 January 2009 Pages: 657 - 663
Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study Mark P. SaundersRichard WilsonEric Van Cutsem Original Article 29 January 2009 Pages: 665 - 672
Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer Franco NolèD. CrivellariA. Goldhirsch Original Article 31 January 2009 Pages: 673 - 680
The microtubule-active antitumor compound TTI-237 has both paclitaxel-like and vincristine-like properties Carl F. BeyerNan ZhangJames J. Gibbons Original Article 10 January 2009 Pages: 681 - 689
Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species Joshua Ö. HaznedarShem PatynaEllen Y. Wu Original Article 25 January 2009 Pages: 691 - 706
Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer Gyeong-Won LeeHye Jung KimJung Hun Kang Original Article 17 January 2009 Pages: 707 - 713
Indomethacin overcomes doxorubicin resistance by decreasing intracellular content of glutathione and its conjugates with decreasing expression of γ-glutamylcysteine synthetase via promoter activity in doxorubicin-resistant leukemia cells Takeshi AsanoArisa Tsutsuda-AsanoYoshitaka Fukunaga Original Article 20 January 2009 Pages: 715 - 721
SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples Andrew ConroyDavid E. StockettRachael Elizabeth Hawtin Original Article 24 January 2009 Pages: 723 - 732
Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma Pooja HingoraniWendong ZhangE. Anders Kolb Original Article 18 February 2009 Pages: 733 - 740
Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine Charles O. NobleZexiong GuoDaryl C. Drummond Original Article Open access 30 January 2009 Pages: 741 - 751
Molecular hydrogen alleviates nephrotoxicity induced by an anti-cancer drug cisplatin without compromising anti-tumor activity in mice Naomi Nakashima-KamimuraTakashi MoriShigeo Ohta Original Article 16 January 2009 Pages: 753 - 761
A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen Paul RuffD. A. VorobiofL. J. Burgess Original Article 25 February 2009 Pages: 763 - 768
Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) Alba A. BrandesA. TosoniM. Reni Original Article Open access 24 January 2009 Pages: 769 - 775
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer Ramesh K. RamanathanChandra P. BelaniDavid R. Gandara Original Article 24 January 2009 Pages: 777 - 783
A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer Vasiliki BozionelouKostas KalbakisDimitris Mavroudis Original Article 22 January 2009 Pages: 785 - 791
Pro-apoptotic and cytostatic activity of naturally occurring cardenolides Elena BloiseAlessandra BracaMaria Antonietta Belisario Original Article 28 January 2009 Pages: 793 - 802
Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors Anna C. PavlickJennifer WuFranco Muggia Original Article 17 February 2009 Pages: 803 - 810
Doxorubicin-induced mitochondrial dysfunction is secondary to nuclear p53 activation in H9c2 cardiomyoblasts Vilma A. SardãoPaulo J. OliveiraKendall B. Wallace Original Article 30 January 2009 Pages: 811 - 827
Carbonate and carbamate derivatives of 4-demethylpenclomedine as novel anticancer agents Lee Roy MorganRobert F. StruckBranko S. Jursic Original Article Open access 03 March 2009 Pages: 829 - 835
Protection of mouse bone marrow from etoposide-induced genomic damage by dexrazoxane Sabry M. AttiaAlaa A. Al-AnteetMohammed M. Al-harbi Original Article 30 January 2009 Pages: 837 - 845
Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity Johnson J. LiuStephen M. F. JamiesonMark J. McKeage Original Article 24 May 2009 Pages: 847 - 856
Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation Agustin CornejoMary BohnenblustGregory A. Abrahamian Short Communication 09 July 2009 Pages: 857 - 860
MTT assays can underestimate cell numbers Wai M. LiuAngus G. Dalgleish Letter to the Editor 14 June 2009 Pages: 861 - 862
